advertising
-
1.
Abdissa D, Hamba N, Kene K, et al: Prevalence and determinants of peripheral neuropathy among type 2 adult diabetes patients attending Jimma University Medical Center, Southwest Ethiopia, 2019, an institutional-based cross-sectional study. J Diabetes Res 2020: 9562920, 2020.
-
2.
Abdissa D: Prevalence and associated factors of painful diabetic peripheral neuropathy among diabetic patients on follow up at Jimma University Medical Center. J Diabetes Metab Disord 19: 1407, 2020.
-
3.
Ponirakis G, Elhadd T, Chinnaiyan S, et al: Prevalence and risk factors for diabetic neuropathy and painful diabetic neuropathy in primary and secondary healthcare in Qatar. J Diabetes Investig 12: 592, 2021.
-
4.
Mathiyalagen P, Kanagasabapathy S, Kadar Z, et al: Prevalence and determinants of peripheral neuropathy among adult type II diabetes mellitus patients attending a non-communicable disease clinic in rural South India. Cureus 13: e15493, 2021.
-
5.
Ahmed MA, Muntingh G, Rheeder P: Vitamin B12 deficiency in metformin-treated type-2 diabetes patients, prevalence and association with peripheral neuropathy. BMC Pharmacol Toxicol 17: 44, 2016.
-
6.
Aleidan FAS, Ahmad BA, Alotaibi FA, et al: Prevalence and risk factors for diabetic peripheral neuropathy among Saudi hospitalized diabetic patients: a nested case-control study. Int J Gen Med 13: 881, 2020.
-
7.
Carmichael J, Fadavi H, Ishibashi F, et al: Advances in screening, early diagnosis and accurate staging of diabetic neuropathy. Front Endocrinol (Lausanne) 12: 671257, 2021.
-
8.
Hashem MM, Esmael A, Nassar AK, et al: The relationship between exacerbated diabetic peripheral neuropathy and metformin treatment in type 2 diabetes mellitus. Sci Rep 11: 1940, 2021.
-
9.
Hicks CW, Selvin E: Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep 19: 86, 2019.
-
10.
Li Z, Lei X, Xu B, et al: Analysis of risk factors of diabetes peripheral neuropathy in type 2 diabetes mellitus and nursing intervention. Exp Ther Med 20: 127, 2020.
-
11.
Lu Y, Xing P, Cai X, et al: Prevalence and risk factors for diabetic peripheral neuropathy in type 2 diabetic patients from 14 countries: estimates of the INTERPRET-DD Study. Front Public Health 8: 534372, 2020.
-
12.
Wu B, Niu Z, Hu F: Study on risk factors of peripheral neuropathy in type 2 diabetes mellitus and establishment of prediction model. Diabetes Metab J 45: 526, 2021.
-
13.
Liu X, Xu Y, An M, et al: The risk factors for diabetic peripheral neuropathy: a meta-analysis. PLoS One 14: e0212574, 2019.
-
14.
Feldman EL, Callaghan BC, Pop-Busui R, et al: Diabetic neuropathy. Nat Rev Dis Primers 5: 42, 2019.
-
15.
Braffett BH, Gubitosi-Klug RA, Albers JW, et al; DCCT/EDIC Research Group: Risk factors for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 69: 1000, 2020.
-
16.
Casadei G, Filippini M, Brognara L: Glycated hemoglobin (HbA1c) as a biomarker for diabetic foot peripheral neuropathy. Diseases 9: 16, 2021.
-
17.
Mayeda L, Katz R, Ahmad I, et al: Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care 8: e000991, 2020.
-
18.
D’Souza M, Kulkarni V, Bhaskaran U, et al: Diabetic peripheral neuropathy and its determinants among patients attending a tertiary health care centre in Mangalore, India. J Public Health Res 4: 450, 2015.
-
19.
Ponirakis G, Elhadd T, Chinnaiyan S, et al: Prevalence and risk factors for painful diabetic neuropathy in secondary healthcare in Qatar. J Diabetes Investig 10: 1558, 2019.
-
20.
Kisozi T, Mutebi E, Kisekka M, et al: Prevalence, severity and factors associated with peripheral neuropathy among newly diagnosed diabetic patients attending Mulago hospital: a cross-sectional study. Afr Health Sci 17: 463, 2017.
-
21.
Gebabo TF, Zewdie TH, Shagaro SS, et al: Determinants of peripheral neuropathy among diabetic patients under follow-up in chronic care clinics of public hospitals at Gamo and Gofa zones, southern Ethiopia. PLoS One 16: e0246722, 2021.
-
22.
Shiferaw WS, Akalu TY, Work Y, et al: Prevalence of diabetic peripheral neuropathy in Africa: a systematic review and meta-analysis. BMC Endocr Disord 20: 49, 2020.
-
23.
Ogbera AO, Adeleye O, Solagberu B, et al: Screening for peripheral neuropathy and peripheral arterial disease in persons with diabetes mellitus in a Nigerian University Teaching Hospital. BMC Res Notes 8: 533, 2015.
-
24.
World Health Organization: WHO STEPS Surveillance Manual 2017: The WHO STEPwise Approach to Chronic Disease Risk Factor Surveillance/Part 3: Training & Practical Guides. Section 5: Guide to Physical Measurements (Step 2), World Health Organization, Geneva, 2017. Available at: https://cdn.who.int/media/docs/default-source/ncds/ncd-surveillance/steps/part3-section5.pdf?sfvrsn=a46653c7_2. Accessed February 25, 2025.
-
25.
British Columbia Provincial Nursing Skin and Wound Care Committee: Procedure: Ankle Brachial Index (ABI) in Adults Using a Handheld Doppler, British Columbia Provincial Nursing Skin and Wound Committee, May 2014. Available at: https://www.clwk.ca/get-resource/ankle-brachial-index-hand-held-doppler-procedure/. Accessed February 25, 2025.
-
26.
American Diabetes Association: 6. Glycemic targets: Standards of Medical Care in Diabetes-2021. Diabetes Care 44(suppl 1): S73, 2021.
- PubMed Citation
- Article by Yakubu Lawal
- Article by Rifkatu Mshelia-Reng
- Article by Special Odiase Omonua
- Article by Kenechukwu Odumodu
- Article by Ramatu Shuaibu
- Article by Ukamaka Dorothy Itanyi
- Article by Amina Ibrahim Abubakar
- Article by Hadijat Oluseyi Kolade-Yunusa
- Article by Zumnan Songden David
- Article by Babajide Ogunlana
- Article by Andrew Clarke
- Article by Olufemi Adediran
- Article by Caleb O. Ehusani
- Article by Zulfiqarali Abbas
- Article by Felicia Ehusani Anumah
- Similar articles in PubMed
Predictors of Peripheral Neuropathy Among Persons with Diabetes Mellitus: A Multicenter Cross-Sectional Study
Search for other papers by Yakubu Lawal in
Current site
Google Scholar
PubMed
Search for other papers by Rifkatu Mshelia-Reng in
Current site
Google Scholar
PubMed
Search for other papers by Special Odiase Omonua in
Current site
Google Scholar
PubMed
Search for other papers by Kenechukwu Odumodu in
Current site
Google Scholar
PubMed
Search for other papers by Ramatu Shuaibu in
Current site
Google Scholar
PubMed
Search for other papers by Ukamaka Dorothy Itanyi in
Current site
Google Scholar
PubMed
Search for other papers by Amina Ibrahim Abubakar in
Current site
Google Scholar
PubMed
Search for other papers by Hadijat Oluseyi Kolade-Yunusa in
Current site
Google Scholar
PubMed
Search for other papers by Zumnan Songden David in
Current site
Google Scholar
PubMed
Search for other papers by Babajide Ogunlana in
Current site
Google Scholar
PubMed
Search for other papers by Andrew Clarke in
Current site
Google Scholar
PubMed
Search for other papers by Olufemi Adediran in
Current site
Google Scholar
PubMed
Search for other papers by Caleb O. Ehusani in
Current site
Google Scholar
PubMed
Search for other papers by Zulfiqarali Abbas in
Current site
Google Scholar
PubMed
Search for other papers by Felicia Ehusani Anumah in
Current site
Google Scholar
PubMed
Background: Diabetic peripheral neuropathy (DPN) is a microvascular complication of diabetes mellitus (DM) that causes substantial morbidities, including pain, foot ulcers, lower-limb amputations, and depression. It is said to affect approximately 50% of adults with DM. Understanding the predictors of DPN will help refocus on early preventive strategies to reduce its numerous morbidities.
Methods: A total of 1,040 persons with DM were consecutively enrolled. Relevant medical history, clinical examinations, and laboratory investigations were performed. Multiple logistic regression was used to determine predictors of DPN. Significance was set at P ≤ .05.
Results: Significant predictors of DPN included age (odds ratio [OR], 1.99; P = .003); female sex (OR, 1.94; P = .023); DM duration (OR, 2.01; P = .032); history of systemic hypertension (OR, 1.68; P = .037); height (OR, 2.02; P = .001); generalized obesity (OR, 2.02; P = .002); central obesity (OR, 1.12; P = .047); poor control of systolic blood pressure (OR, 1.78; P = .001), diastolic blood pressure (OR, 1.45; P = .006), fasting plasma glucose (OR, 2.43; P = .004), 2-hour postprandial glucose (2HrPP) (OR, 2.83; P = .001), and glycated hemoglobin (OR, 2.31; P = .004); and peripheral artery disease (OR, 1.89; P = .002). The negative predictors of DPN include antidiabetics (OR, 2.39; P = .008), antihypertensives (OR, 2.45; P = .009), statins (OR, 2.21; P = .004), and antiplatelets (OR, 2.46; P = .030).
Conclusions: Significant predictors of DPN include age, DM duration, female sex, height, history of systemic hypertension, and obesity. Others include poor control of systolic and diastolic blood pressure, fasting plasma glucose, 2HrPP, and glycated hemoglobin levels. Negative predictors include antidiabetics, antihypertensives, statins, and antiplatelets.
advertising
